For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.
Study of an Investigational Drug to Treat Hepatitis B
The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of an investigational drug to treat patients with hepatitis B. Two different doses of the drug will be investigated compared to a placebo. The treatment will be assigned randomly. A total of approximately 140 subjects with hepatitis B will be enrolled. At Rush University Medical Center, we expect to recruit 2 patients.
In order to participate you must meet the following criteria:
- Have chronic hepatitis B.
- Have not been previously treated for hepatitis B or have not been treat for hepatitis B within 6 months of entering the study.
- Have had a Fibroscan liver stiffness measurement less than 8.0 kPa within 6 months prior to entering the study.
You will be excluded from the study if any of the following criteria apply to you:
- Are co-infected with hepatitis A, C, D, E or HIV.
- Have any evidence of hepatic decompensation.
- Have any evidence of liver disease of non-HBV etiology.
This is a partial list of elgibility requirements.